2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Related Products

PDF 4.17 MB

Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules.

Phosphodiesterase (PDE) Isoform Specific Products:

Phosphodiesterase (PDE) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-19929A
    (R)-Tanimilast
    		Inhibitor 99.72%
    (R)-Tanimilast is a isomeride of Tanimilast (HY-19929). Tanimilast (CHF-6001) is a novel highly potent and selective phosphodiesterase 4 inhibitor (IC50=0.026 nM).
    (R)-Tanimilast
  • HY-150614
    Autotaxin-IN-6
    		Inhibitor 99.88%
    Autotaxin-IN-6 (compound 23) is a potent autotaxin (ATX) inhibitor with an IC50 value of 30 nM. Autotaxin-IN-6 can reduce cell migration. Autotaxin-IN-6 can be used for researching anticancer.
    Autotaxin-IN-6
  • HY-P2867
    Phosphodiesterase II, Bovine Spleen
    Phosphodiesterase II (EC 3.1.16.1), namely phosphodiesterase 2, is mainly involved in the hydrolysis of the important second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), and is often used in biochemical research. Phosphodiesterase II is expressed in a variety of tissues, such as the adrenal medulla, brain, heart, platelets, macrophages and endothelial cells, and is involved in the regulation of many different intracellular processes.
    Phosphodiesterase II, Bovine Spleen
  • HY-143237
    ATX inhibitor 11
    		Inhibitor 99.44%
    ATX inhibitor 11 (compound 13c) is a potent ATX (autotaxin) inhibitor, with an IC50 of 2.7 nM. ATX inhibitor 11 can typically alleviate the severity of fibrosis tissues and effectively reduce the deposition of fibrotic biomarker α-SMA in mice fibrosis model. ATX inhibitor 11 can be used for lung fibrosis research.
    ATX inhibitor 11
  • HY-114727
    PDE7-IN-4
    		98.55%
    PDE7-IN-4 is a phosphodiesterase 7 (PDE7) inhibitor with activity that increases intracellular cyclic adenosine monophosphate (cAMP) levels. PDE7-IN-4 shows potential inhibitory effects in neurotransmission and anti-inflammatory applications. PDE7-IN-4 exerts its biological activity by acting on the cAMP/cAMP response element binding protein (CREB) pathway. The development of PDE7-IN-4 aims to improve its pharmacokinetic characteristics to more effectively target neurodegenerative diseases and other inflammation-related diseases.
    PDE7-IN-4
  • HY-108622
    Mesopram
    		Inhibitor 98.80%
    Mesopram (Daxalipram) is an orally active phosphodiesterase (PDE) 4 inhibitor. Mesopram inhibits the synthesis of proinflammatory cytokines TNF-α and IFN-γ. Mesopram demonstrates efficacy in ameliorating Dextran sulfate sodium (DSS) (HY-116282C)-induced murine colitis. Mesopram can be used for the study of chronic inflammatory diseases.
    Mesopram
  • HY-101705
    Tibenelast sodium
    		Inhibitor 99.66%
    Tibenelast sodium is a phosphodiesterase inhibitor.
    Tibenelast sodium
  • HY-12085S
    Apremilast-d5
    		Inhibitor 99.26%
    Apremilast-d5 is a deuterium labeled Apremilast. Apremilast is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM.
    Apremilast-d<sub>5</sub>
  • HY-P1077
    CALP1
    		Activator 98.44%
    CALP1 is a calmodulin (CaM) agonist (Kd of 88 µM) with binding to the CaM EF-hand/Ca2+-binding site. CALP1 blocks calcium influx and apoptosis (IC50 of 44.78 µM) through inhibition of calcium channel opening. CALP1 blocks glutamate receptor channels and blocks a store-operated nonselective cation channel. CALP1 activates CaM-dependent phosphodiesterase activity.
    CALP1
  • HY-12813
    PDE10-IN-1
    		Inhibitor 99.44%
    PDE10-IN-1 is a potent PDE10-IN-1 inhibitor extracted from Patent WO 2013192273 A1, for treating CNS and metabolic disorders.
    PDE10-IN-1
  • HY-105349
    T-0156
    		Inhibitor
    T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC50=0.23 nM). T-0156 inhibits PDE6 (IC50=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC50>10 μM). T-0156 enhances the nitric oxide (NO)/cGMP pathway.
    T-0156
  • HY-147830
    PDE4B-IN-3
    		Inhibitor 99.37%
    PDE4B-IN-3 is a potent PDE4B inhibitor with an IC50 of 0.94 μM. PDE4B-IN-3 has anti-inflammatory activities.
    PDE4B-IN-3
  • HY-14550A
    PDE10-IN-5
    		Inhibitor 99.92%
    PDE10-IN-5 is a phosphodiesterase 10 (PDE 10) inhibitor, can be used for researching certain central nervous system (CNS) disorders.
    PDE10-IN-5
  • HY-157886
    TDP1 Inhibitor-3
    		Inhibitor 98.10%
    TDP1 Inhibitor-3 (Compound 4E) is a (TDP1) inhibitor with an IC50 value of 0.63 μM.
    TDP1 Inhibitor-3
  • HY-151916
    Enpp/Carbonic anhydrase-IN-1
    		Inhibitor 99.57%
    Enpp/Carbonic anhydrase-IN-1 (compound 1e) is a potent Enpp and carbonic anhydrase inhibitor with IC50s of 1.36, 1.35, 3.00, 0.88, 1.02 μM for NPP1, NPP2, NPP3, CA-II, CA-IX respectively. Enpp/Carbonic anhydrase-IN-1 shows antiproliferative activity for cancer cells and low cytotoxic against normal cells. Enpp/Carbonic anhydrase-IN-1 induces Apoptosis.
    Enpp/Carbonic anhydrase-IN-1
  • HY-116100
    (E/Z)-HA155
    		Inhibitor 99.26%
    (E/Z)-HA155 is a potent autotaxin (ATX) type I inhibitor. (E/Z)-HA155 can be used for researching cancer, fibrotic diseases, inflammation, pain and angiogenesis.
    (E/Z)-HA155
  • HY-101693A
    Senazodan hydrochloride
    		Inhibitor 99.84%
    Senazodan (MCI 154) (hydrochloride), as a Ca2+ sensitiser, shows inhibition effect on PDE III.
    Senazodan hydrochloride
  • HY-U00179
    CDC801
    		Inhibitor 98.94%
    CDC801 is a potent and orally active phosphodiesterase 4 (PDE4) and tumor necrosis factor-α (TNF-α) inhibitor with IC50 of 1.1 μM and 2.5 μM, respectively.
    CDC801
  • HY-10978R
    Crisaborole (Standard)
    		Inhibitor
    Crisaborole (Standard) is the analytical standard of Crisaborole. This product is intended for research and analytical applications. Crisaborole (AN-2728) is a potent inhibitor of PDE4 and cytokine release; inhibit PDE4 with an IC50 of 0.49 μM.
    Crisaborole (Standard)
  • HY-130786
    Denbufylline
    		Inhibitor 99.92%
    Denbufylline (BRL 30892) is an inhibitor of phosphodiesterase-4 (PDE4). Denbufylline is able to block the degradation of intracellular cAMP (cyclic adenosine phosphate) thereby increasing the level of intracellular cAMP, which helps regulate a variety of cellular functions. Denbufylline can be used in the study of chronic obstructive pulmonary disease (COPD), asthma and other inflammatory diseases.
    Denbufylline
Cat. No. Product Name / Synonyms Application Reactivity
Phosphodiesterase (PDE) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.